Reading the Risankizumab Claims Data: Protopathic Bias and Study Limitations

"Reading the Risankizumab Claims Data: Protopathic Bias and Study Limitations" weighs what the data can and cannot support.

Dr. Strober turns to a candid critique of the study. He praises its scale, noting 20,000 patients is large, and its use of the standard 2026 biologics across the spectrum. He calls the design rigorous for a claims analysis, since it works hard to remove patients who already had psoriatic arthritis and to verify a pure psoriasis population followed over time. Demographics, ages, and comorbidities were well balanced.

He then details the weaknesses. The most likely, he says, is protopathic bias: patients started on IL-17 inhibitors or TNF blockers may have subtle, uncoded signs of psoriatic arthritis, prompting clinicians to choose agents already indicated for joint disease. Because those classes reached the psoriatic arthritis market earlier, there is a channeling effect. That channeling makes a later psoriatic arthritis code more likely in those patients than in people placed on an IL-23 inhibitor, which tends to be chosen for skin-predominant disease.

Dr. Strober also raises residual confounding, since claims data omit psoriasis severity measures like body surface area or PASI, obesity status, family history, and physical signs such as dactylitis or enthesitis. He adds surveillance bias, where patients on TNF or IL-17 inhibitors may receive more aggressive joint monitoring, generating more coding.

For these reasons, he cautions the audience not to treat the findings as conclusive proof that IL-23 inhibition, and risankizumab specifically, prevents psoriatic arthritis better than IL-17 inhibition. He frames claims analyses of this kind as hypothesis-generating. The real answer, he argues, requires prospective randomized controlled trials that enroll truly arthritis-negative, treatment-naive patients and follow them over time.

In " Skin Clearance and PsA Prevention with Biologics in Psoriasis," Dr. Strober closes with how he translates all of this into everyday treatment decisions.